RDEA3170 10 mg

DRUG6 trials

Sponsors

Ardea Biosciences, Inc.

Conditions

GoutHealthy

Phase 1

RDEA3170 and Febuxostat Drug Interaction Study

CompletedNCT01883167

Ardea Biosciences, Inc.Healthy

Start: 2013-06-30End: 2013-12-31Updated: 2014-01-09

RDEA3170 AME Study

CompletedNCT01910506

Ardea Biosciences, Inc.Healthy

Start: 2013-08-31End: 2013-11-30Updated: 2014-01-09

RDEA3170 and Allopurinol Combination Study in Gout Subjects

CompletedNCT02279641

Ardea Biosciences, Inc.Gout

Start: 2014-11-01End: 2015-09-11Updated: 2017-12-20

RDEA3170 Bioavailability Study

CompletedNCT02336594

Ardea Biosciences, Inc.Gout

Start: 2014-11-30End: 2015-03-31Updated: 2017-10-13

Phase 2

RDEA3170 Monotherapy in Subjects With Gout

CompletedNCT01927198

Ardea Biosciences, Inc.Gout

Start: 2013-08-31End: 2014-07-31Updated: 2015-07-01

RDEA3170 and Febuxostat Combination Study in Gout Subjects

CompletedNCT02246673

Ardea Biosciences, Inc.Gout

Start: 2014-10-31End: 2016-02-29Updated: 2017-07-27

Related Papers

Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

2020-09-195 citations

Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

Modern Rheumatology2018-10-1850 citations

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study

RMD Open2018-04-0113 citations

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

RMD Open2018-02-0139 citations